{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:35:29Z","timestamp":1761514529916},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11864-020-0708-4","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:02:36Z","timestamp":1581408156000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives"],"prefix":"10.1007","volume":"21","author":[{"given":"Nasr","family":"Alrabadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed K.","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"issue":"4","key":"708_CR1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"708_CR2","doi-asserted-by":"crossref","first-page":"5986129","DOI":"10.1155\/2017\/5986129","volume":"2017","author":"B Busser","year":"2017","unstructured":"Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int. 2017;2017:5986129.","journal-title":"Biomed Res Int"},{"key":"708_CR3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre L, Warburton L, Millward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62\u20139.","journal-title":"Cancer Lett"},{"issue":"1","key":"708_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","volume":"17","author":"SY Lim","year":"2018","unstructured":"Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H. Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018;17(1):8.","journal-title":"Mol Cancer"},{"issue":"4","key":"708_CR5","first-page":"405","volume":"16","author":"MR Gaiser","year":"2018","unstructured":"Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS. Liquid biopsy to monitor melanoma patients. J Dtsch Dermatol Ges. 2018;16(4):405\u201314.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"708_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/annonc\/mdx766","volume":"29","author":"M Yang","year":"2018","unstructured":"Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, et al. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol. 2018;29(2):311\u201323.","journal-title":"Ann Oncol"},{"issue":"1","key":"708_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-018-0398-x","volume":"20","author":"RJ Diefenbach","year":"2019","unstructured":"Diefenbach RJ, Lee JH, Rizos H. Monitoring melanoma using circulating free DNA. Am J Clin Dermatol. 2019;20(1):1\u201312.","journal-title":"Am J Clin Dermatol"},{"key":"708_CR8","doi-asserted-by":"crossref","unstructured":"\u2022 Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1\u20139 A prospective cohort study showed that total cfDNA is a sufficient indicator of tumor burden (TB) and can represent a prognostic biomarker for patients with metastatic melanoma.","DOI":"10.1016\/j.ejca.2017.10.029"},{"issue":"10","key":"708_CR9","first-page":"1947","volume":"8","author":"L Li","year":"2018","unstructured":"Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 2018;8(10):1947\u201356.","journal-title":"Am J Cancer Res"},{"key":"708_CR10","doi-asserted-by":"crossref","unstructured":"Alrabadi N, Gibson N, Curless K, Cheng L, Kuhar M, Chen S, et al. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod Pathol. (3):330\u20137.","DOI":"10.1038\/s41379-018-0161-0"},{"key":"708_CR11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fonc.2018.00178","volume":"8","author":"SA Hogan","year":"2018","unstructured":"Hogan SA, Levesque MP, Cheng PF. Melanoma immunotherapy: next-generation biomarkers. Front Oncol. 2018;8:178.","journal-title":"Front Oncol"},{"issue":"3","key":"708_CR12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","volume":"6","author":"MR Girotti","year":"2016","unstructured":"Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, et al. Application of sequencing, liquid biopsies, and patient-derived Xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6(3):286\u201399.","journal-title":"Cancer Discov"},{"issue":"1","key":"708_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-016-9652-y","volume":"36","author":"Y Khagi","year":"2017","unstructured":"Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36(1):179\u201390.","journal-title":"Cancer Metastasis Rev"},{"issue":"19","key":"708_CR14","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","volume":"23","author":"Y Khagi","year":"2017","unstructured":"Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729\u201336.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"708_CR15","doi-asserted-by":"crossref","first-page":"e0188174","DOI":"10.1371\/journal.pone.0188174","volume":"12","author":"F Koeppel","year":"2017","unstructured":"Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12(11):e0188174.","journal-title":"PLoS One"},{"issue":"1","key":"708_CR16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner A, Battke F, Hadaschik D, Schulze M, Weissgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma: results of a prospective biomarker study. J Immunotherapy of Cancer. 2019;7(1):180.","journal-title":"J Immunotherapy of Cancer"},{"issue":"7","key":"708_CR17","doi-asserted-by":"crossref","first-page":"e0197333","DOI":"10.1371\/journal.pone.0197333","volume":"13","author":"S Hellwig","year":"2018","unstructured":"Hellwig S, Nix DA, Gligorich KM, O'Shea JM, Thomas A, Fuertes CL, et al. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018;13(7):e0197333.","journal-title":"PLoS One"},{"issue":"2","key":"708_CR18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1878-0261.12391","volume":"13","author":"L Calapre","year":"2019","unstructured":"Calapre L, Giardina T, Robinson C, Reid AL, Al-Ogaili Z, Pereira MR, et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol. 2019;13(2):171\u201384.","journal-title":"Mol Oncol"},{"issue":"3","key":"708_CR19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00428-018-2393-2","volume":"473","author":"ML Zhu","year":"2018","unstructured":"Zhu ML, Zhou L, Sadri N. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma. Virchows Arch. 2018;473(3):371\u20137.","journal-title":"Virchows Arch"},{"issue":"10","key":"708_CR20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","volume":"15","author":"L Cabel","year":"2018","unstructured":"Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018;15(10):639\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"39","key":"708_CR21","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318.","journal-title":"Oncotarget."},{"issue":"5","key":"708_CR22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130\u20136.","journal-title":"Ann Oncol"},{"issue":"5","key":"708_CR23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717\u201321.","journal-title":"JAMA Oncol"},{"key":"708_CR24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-9773-2_7","volume":"2055","author":"MM Syeda","year":"2020","unstructured":"Syeda MM, Wiggins JM, Corless B, Spittle C, Karlin-Neumann G, Polsky D. Validation of circulating tumor DNA assays for detection of metastatic melanoma. Methods Mol Biol. 2020;2055:155\u201380.","journal-title":"Methods Mol Biol"},{"issue":"15","key":"708_CR25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.clinbiochem.2014.12.007","volume":"48","author":"AL Reid","year":"2015","unstructured":"Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999\u20131002.","journal-title":"Clin Biochem"},{"issue":"1","key":"708_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CMR.0000000000000510","volume":"29","author":"MC Scaini","year":"2019","unstructured":"Scaini MC, Pigozzo J, Pizzi M, Manicone M, Chiarion-Sileni V, Zambenedetti P, et al. Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Res. 2019;29(1):89\u201394.","journal-title":"Melanoma Res"},{"key":"708_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/CBM-181647","volume":"26","author":"F Salvianti","year":"2019","unstructured":"Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. Cancer Biomark. 2019;26:271.","journal-title":"Cancer Biomark"},{"key":"708_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.013","volume":"424","author":"G Marsavela","year":"2018","unstructured":"Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M. Melanoma circulating tumor cells: benefits and challenges required for clinical application. Cancer Lett. 2018;424:1\u20138.","journal-title":"Cancer Lett"},{"issue":"10","key":"708_CR29","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1073\/pnas.1719264115","volume":"115","author":"X Hong","year":"2018","unstructured":"Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115(10):2467\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"708_CR30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/cancers11020157","volume":"11","author":"C Aya-Bonilla","year":"2019","unstructured":"Aya-Bonilla C, Gray ES, Manikandan J, Freeman JB, Zaenker P, Reid AL, et al. Immunomagnetic-enriched subpopulations of melanoma circulating tumour cells (CTCs) exhibit distinct transcriptome profiles. Cancers. 2019;11(2):157.","journal-title":"Cancers"},{"issue":"5","key":"708_CR31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804\u201314.","journal-title":"Ann Oncol"},{"issue":"4","key":"708_CR32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/gtmb.2018.0193","volume":"23","author":"T Burjanivova","year":"2019","unstructured":"Burjanivova T, Malicherova B, Grendar M, Minarikova E, Dusenka R, Vanova B, et al. Detection of BRAFV600E mutation in melanoma patients by digital PCR of circulating DNA. Genet Test Mol Biomarkers. 2019;23(4):241\u20135.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"90","key":"708_CR33","doi-asserted-by":"crossref","first-page":"36238","DOI":"10.18632\/oncotarget.26343","volume":"9","author":"E Long-Mira","year":"2018","unstructured":"Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudie H, Tanga V, et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018;9(90):36238\u201349.","journal-title":"Oncotarget."},{"issue":"2","key":"708_CR34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/00015555-3080","volume":"99","author":"L Keller","year":"2019","unstructured":"Keller L, Guibert N, Casanova A, Brayer S, Farella M, Delaunay M, et al. Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm Venereol. 2019;99(2):206\u201310.","journal-title":"Acta Derm Venereol"},{"key":"708_CR35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3389\/fphar.2018.00856","volume":"9","author":"R Salemi","year":"2018","unstructured":"Salemi R, Falzone L, Madonna G, Polesel J, Cina D, Mallardo D, et al. MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAF(V600E) mutation detected in circulating-free DNA. Front Pharmacol. 2018;9:856.","journal-title":"Front Pharmacol"},{"issue":"38","key":"708_CR36","doi-asserted-by":"crossref","first-page":"25265","DOI":"10.18632\/oncotarget.25404","volume":"9","author":"G Herbreteau","year":"2018","unstructured":"Herbreteau G, Vallee A, Knol AC, Theoleyre S, Quereux G, Varey E, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265\u201376.","journal-title":"Oncotarget"},{"key":"708_CR37","first-page":"76","volume":"276","author":"D Shapochka","year":"2018","unstructured":"Shapochka D, Shapochka T, Seleznyov O, Matveeva A, Dudin V. Use of circulating tumor dna for detection of braf v600e mutation and treatment monitoring in melanoma patients. Georgian Med News. 2018;276:76\u201381.","journal-title":"Georgian Med News"},{"issue":"10","key":"708_CR38","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2340\/00015555-2748","volume":"97","author":"A Ashida","year":"2017","unstructured":"Ashida A, Sakaizawa K, Uhara H, Okuyama R. Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients. Acta Derm Venereol. 2017;97(10):1212\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"45","key":"708_CR39","doi-asserted-by":"crossref","first-page":"78890","DOI":"10.18632\/oncotarget.20354","volume":"8","author":"AC McEvoy","year":"2017","unstructured":"McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget. 2017;8(45):78890\u2013900.","journal-title":"Oncotarget"},{"issue":"1","key":"708_CR40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","volume":"17","author":"T Seremet","year":"2019","unstructured":"Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.","journal-title":"J Transl Med"},{"issue":"2","key":"708_CR41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1878-0261.12415","volume":"13","author":"LF van Dessel","year":"2019","unstructured":"van Dessel LF, Vitale SR, Helmijr JCA, Wilting SM, van der Vlugt-Daane M, Oomen-de Hoop E, et al. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. Mol Oncol. 2019;13(2):392\u2013402.","journal-title":"Mol Oncol"},{"issue":"3","key":"708_CR42","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nano.2017.12.009","volume":"14","author":"J Klump","year":"2018","unstructured":"Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, et al. Extracellular vesicles or free circulating DNA: where to search for BRAF and cKIT mutations? Nanomedicine. 2018;14(3):875\u201382.","journal-title":"Nanomedicine"},{"key":"708_CR43","doi-asserted-by":"crossref","unstructured":"\u2022 Garcia-Silva S, Benito-Martin A, Sanchez-Redondo S, Hernandez-Barranco A, Ximenez-Embun P, Nogues L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF (V600E) mutation. J Exp Med. 2019;216(5):1061\u201370 A clinical study where the investigators were able to detect BRAFV600E mutation in the extracellular vesicles from lymphatic drainage of some melanoma patients who were at higher risk of cancer relapse.","DOI":"10.1084\/jem.20181522"},{"issue":"5","key":"708_CR44","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20181618","volume":"216","author":"MAS Broggi","year":"2019","unstructured":"Broggi MAS, Maillat L, Clement CC, Bordry N, Corthesy P, Auger A, et al. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. J Exp Med. 2019;216(5):1091\u2013107.","journal-title":"J Exp Med"},{"issue":"7","key":"708_CR45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/cells8070755","volume":"8","author":"L Cayrefourcq","year":"2019","unstructured":"Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, et al. S100-EPISPOT: a new tool to detect viable circulating melanoma cells. Cells. 2019;8(7):755.","journal-title":"Cells"},{"issue":"11","key":"708_CR46","doi-asserted-by":"crossref","first-page":"e0206942","DOI":"10.1371\/journal.pone.0206942","volume":"13","author":"FC Svedman","year":"2018","unstructured":"Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. PLoS One. 2018;13(11):e0206942.","journal-title":"PLoS One"},{"issue":"7","key":"708_CR47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41418-018-0205-5","volume":"26","author":"L Fattore","year":"2019","unstructured":"Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2019;26(7):1267\u201382.","journal-title":"Cell Death Differ"},{"key":"708_CR48","doi-asserted-by":"crossref","unstructured":"Mumford SL, Towler BP, Pashler AL, Gilleard O, Martin Y, Newbury SF. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules. 2018;8(2).","DOI":"10.3390\/biom8020021"},{"issue":"13","key":"708_CR49","doi-asserted-by":"crossref","first-page":"22262","DOI":"10.18632\/oncotarget.14763","volume":"8","author":"L Fattore","year":"2017","unstructured":"Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8(13):22262\u201378.","journal-title":"Oncotarget"},{"key":"708_CR50","doi-asserted-by":"crossref","unstructured":"Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8).","DOI":"10.3390\/cancers11081170"},{"issue":"2","key":"708_CR51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/pcmr.12422","volume":"29","author":"DC Bennett","year":"2016","unstructured":"Bennett DC. Genetics of melanoma progression: the rise and fall of cell senescence. Pigment Cell Melanoma Res. 2016;29(2):122\u201340.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"708_CR52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.det.2016.08.001","volume":"35","author":"JM Huang","year":"2017","unstructured":"Huang JM, Chikeka I, Hornyak TJ. Melanocytic nevi and the genetic and epigenetic control of oncogene-induced senescence. Dermatol Clin. 2017;35(1):85\u201393.","journal-title":"Dermatol Clin"},{"issue":"2","key":"708_CR53","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ccell.2018.01.002","volume":"33","author":"Y Yu","year":"2018","unstructured":"Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell. 2018;33(2):322\u201336.e8.","journal-title":"Cancer Cell"},{"issue":"9","key":"708_CR54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tcb.2018.04.006","volume":"28","author":"CJ Sieben","year":"2018","unstructured":"Sieben CJ, Sturmlechner I, van de Sluis B, van Deursen JM. Two-step senescence-focused cancer therapies. Trends Cell Biol. 2018;28(9):723\u201337.","journal-title":"Trends Cell Biol"},{"issue":"9","key":"708_CR55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41571-019-0204-6","volume":"16","author":"X Bai","year":"2019","unstructured":"Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNgamma pathways. Nat Rev Clin Oncol. 2019;16(9):549\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"708_CR56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-6670-7_17","volume":"1534","author":"A Joselow","year":"2017","unstructured":"Joselow A, Lynn D, Terzian T, Box NF. Senescence-like phenotypes in human nevi. Methods Mol Biol. 2017;1534:175\u201384.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"708_CR57","doi-asserted-by":"crossref","first-page":"e1006942","DOI":"10.1371\/journal.pgen.1006942","volume":"13","author":"CJ Cairney","year":"2017","unstructured":"Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, et al. A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genet. 2017;13(8):e1006942.","journal-title":"PLoS Genet"},{"key":"708_CR58","doi-asserted-by":"crossref","unstructured":"Carvalho C, L'Hote V, Courbeyrette R, Kratassiouk G, Pinna G, Cintrat JC, et al. Glucocorticoids delay RAF-induced senescence promoted by EGR1. J Cell Sci. 2019;132(16).","DOI":"10.1242\/jcs.230748"},{"issue":"18","key":"708_CR59","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1038\/s41388-018-0632-2","volume":"38","author":"R Kumar","year":"2019","unstructured":"Kumar R, Njauw CN, Reddy BY, Ji Z, Rajadurai A, Klebanov N, et al. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene. 2019;38(18):3504\u201320.","journal-title":"Oncogene."},{"issue":"3","key":"708_CR60","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","volume":"21","author":"L Wang","year":"2017","unstructured":"Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in Cancer. Cell Rep. 2017;21(3):773\u201383.","journal-title":"Cell Rep"},{"issue":"3","key":"708_CR61","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1087057116679592","volume":"22","author":"WJ Lee","year":"2017","unstructured":"Lee WJ, Skalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, et al. Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discov. 2017;22(3):298\u2013308.","journal-title":"SLAS Discov"},{"issue":"5","key":"708_CR62","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.prp.2017.01.010","volume":"213","author":"E Sener","year":"2017","unstructured":"Sener E, Yildirim P, Tan A, Gokoz O, Tezel GG. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. Pathol Res Pract. 2017;213(5):522\u201330.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"708_CR63","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.18632\/oncotarget.14094","volume":"8","author":"W Bruno","year":"2017","unstructured":"Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry. Oncotarget. 2017;8(5):8069\u201382.","journal-title":"Oncotarget."},{"issue":"11","key":"708_CR64","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jclinpath-2017-204367","volume":"70","author":"O O'Brien","year":"2017","unstructured":"O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron C. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol. 2017;70(11):935\u201340.","journal-title":"J Clin Pathol"},{"issue":"1","key":"708_CR65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PAI.0000000000000500","volume":"26","author":"A Felisiak-Golabek","year":"2018","unstructured":"Felisiak-Golabek A, Inaguma S, Kowalik A, Wasag B, Wang ZF, Zieba S, et al. SP174 antibody lacks specificity for NRAS Q61R and cross-reacts with HRAS and KRAS Q61R mutant proteins in malignant melanoma. Appl Immunohistochem Mol Morphol. 2018;26(1):40\u20135.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"708_CR66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0000000000000421","volume":"28","author":"C Bisschop","year":"2018","unstructured":"Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, droplet digital PCR, and the Idylla mutation platform. Melanoma Res. 2018;28(2):96\u2013104.","journal-title":"Melanoma Res"},{"issue":"8","key":"708_CR67","doi-asserted-by":"crossref","first-page":"e0221123","DOI":"10.1371\/journal.pone.0221123","volume":"14","author":"A Vallee","year":"2019","unstructured":"Vallee A, Denis-Musquer M, Herbreteau G, Theoleyre S, Bossard C, Denis MG. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. PLoS One. 2019;14(8):e0221123.","journal-title":"PLoS One"},{"issue":"6","key":"708_CR68","doi-asserted-by":"crossref","first-page":"e0198795","DOI":"10.1371\/journal.pone.0198795","volume":"13","author":"N Chat-Uthai","year":"2018","unstructured":"Chat-Uthai N, Vejvisithsakul P, Udommethaporn S, Meesiri P, Danthanawanit C, Wongchai Y, et al. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS One. 2018;13(6):e0198795.","journal-title":"PLoS One"},{"key":"708_CR69","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Reiter JG, Makohon-Moore AP, Gerold JM, Heyde A, Attiyeh MA, Kohutek ZA, et al. Minimal functional driver gene heterogeneity among untreated metastases. Science (New York, NY). 2018;361(6406):1033\u20137 A clinical study on patients with different cancer types demonstarated that a large majority of driver gene mutations are common to all metastases and that portion which were not shared by all metastases are unlikely to have functional consequences.","DOI":"10.1126\/science.aat7171"},{"key":"708_CR70","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, et al. Patterns of genomic evolution in advanced melanoma. Nat Commun. 2018;9(1):2665 This clinical study showed only a small intermetastatic genetic heterogeneity in melanoma patients, with almost fully similar driver mutations between different lesions.","DOI":"10.1038\/s41467-018-05063-1"},{"key":"708_CR71","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Manca A, Paliogiannis P, Colombino M, Casula M, Lissia A, Botti G, et al. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. J Transl Med. 2019;17(1):289 This clinical study demonstrated a high concordance of mutational patterns when comparing the primary and metastatic cutaneous melanomas.","DOI":"10.1186\/s12967-019-2039-4"},{"issue":"14","key":"708_CR72","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.18632\/aging.102099","volume":"11","author":"X Li","year":"2019","unstructured":"Li X, Cai Y. Better prognostic determination and feature characterization of cutaneous melanoma through integrative genomic analysis. Aging. 2019;11(14):5081\u2013107.","journal-title":"Aging."},{"issue":"20","key":"708_CR73","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926\u201336.","journal-title":"N Engl J Med"},{"issue":"7653","key":"708_CR74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175\u201380.","journal-title":"Nature."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-0708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-020-0708-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-0708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T06:41:47Z","timestamp":1665816107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-020-0708-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-0708-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"11 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nasr Alrabadi, Razan Haddad, and Ahmed K. Alomari declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"19"}}